The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: Potential targets for neurotherapeutics

Edward Pajarillo, Asha Rizor, Jayden Lee, Michael Aschner, Eunsook Lee

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Glutamate is the primary excitatory neurotransmitter in the central nervous system (CNS) which initiates rapid signal transmission in the synapse before its re-uptake into the surrounding glia, specifically astrocytes. The astrocytic glutamate transporters glutamate-aspartate transporter (GLAST) and glutamate transporter-1 (GLT-1) and their human homologs excitatory amino acid transporter 1 (EAAT1) and 2 (EAAT2), respectively, are the major transporters which take up synaptic glutamate to maintain optimal extracellular glutamic levels, thus preventing accumulation in the synaptic cleft and ensuing excitotoxicity. Growing evidence has shown that excitotoxicity is associated with various neurological disorders, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), manganism, ischemia, schizophrenia, epilepsy, and autism. While the mechanisms of neurological disorders are not well understood, the dysregulation of GLAST/GLT-1 may play a significant role in excitotoxicity and associated neuropathogenesis. The expression and function of GLAST/GLT-1 may be dysregulated at the genetic, epigenetic, transcriptional or translational levels, leading to high levels of extracellular glutamate and excitotoxicity. Consequently, understanding the regulatory mechanisms of GLAST/GLT-1 has been an area of interest in developing therapeutics for the treatment of neurological disorders. Pharmacological agents including β-lactam antibiotics, estrogen/selective estrogen receptor modulators (SERMs), growth factors, histone deacetylase inhibitors (HDACi), and translational activators have shown significant efficacy in enhancing the expression and function of GLAST/GLT-1 and glutamate uptake both in vitro and in vivo. This comprehensive review will discuss the regulatory mechanisms of GLAST/GLT-1, their association with neurological disorders, and the pharmacological agents which mediate their expression and function. This article is part of the issue entitled ‘Special Issue on Neurotransmitter Transporters’.

Original languageEnglish (US)
Article number107559
JournalNeuropharmacology
Volume161
DOIs
StatePublished - Dec 15 2019

Fingerprint

Amino Acid Transport System X-AG
Nervous System Diseases
Glutamic Acid
Excitatory Amino Acid Transporter 2
Excitatory Amino Acid Transporter 1
Neurotransmitter Transport Proteins
Pharmacology
Selective Estrogen Receptor Modulators
Lactams
Histone Deacetylase Inhibitors
Amyotrophic Lateral Sclerosis
Autistic Disorder
Epigenomics
Neuroglia
Astrocytes
Synapses
Neurotransmitter Agents
Parkinson Disease

Keywords

  • Astrocytes
  • EAAT1
  • EAAT2
  • Excitatory amino acid transporters
  • Excitotoxicity
  • GLAST
  • GLT-1
  • Glutamate
  • Glutamate transporters

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders : Potential targets for neurotherapeutics. / Pajarillo, Edward; Rizor, Asha; Lee, Jayden; Aschner, Michael; Lee, Eunsook.

In: Neuropharmacology, Vol. 161, 107559, 15.12.2019.

Research output: Contribution to journalReview article

@article{747bd65dde834177adb03360c2b183d2,
title = "The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: Potential targets for neurotherapeutics",
abstract = "Glutamate is the primary excitatory neurotransmitter in the central nervous system (CNS) which initiates rapid signal transmission in the synapse before its re-uptake into the surrounding glia, specifically astrocytes. The astrocytic glutamate transporters glutamate-aspartate transporter (GLAST) and glutamate transporter-1 (GLT-1) and their human homologs excitatory amino acid transporter 1 (EAAT1) and 2 (EAAT2), respectively, are the major transporters which take up synaptic glutamate to maintain optimal extracellular glutamic levels, thus preventing accumulation in the synaptic cleft and ensuing excitotoxicity. Growing evidence has shown that excitotoxicity is associated with various neurological disorders, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), manganism, ischemia, schizophrenia, epilepsy, and autism. While the mechanisms of neurological disorders are not well understood, the dysregulation of GLAST/GLT-1 may play a significant role in excitotoxicity and associated neuropathogenesis. The expression and function of GLAST/GLT-1 may be dysregulated at the genetic, epigenetic, transcriptional or translational levels, leading to high levels of extracellular glutamate and excitotoxicity. Consequently, understanding the regulatory mechanisms of GLAST/GLT-1 has been an area of interest in developing therapeutics for the treatment of neurological disorders. Pharmacological agents including β-lactam antibiotics, estrogen/selective estrogen receptor modulators (SERMs), growth factors, histone deacetylase inhibitors (HDACi), and translational activators have shown significant efficacy in enhancing the expression and function of GLAST/GLT-1 and glutamate uptake both in vitro and in vivo. This comprehensive review will discuss the regulatory mechanisms of GLAST/GLT-1, their association with neurological disorders, and the pharmacological agents which mediate their expression and function. This article is part of the issue entitled ‘Special Issue on Neurotransmitter Transporters’.",
keywords = "Astrocytes, EAAT1, EAAT2, Excitatory amino acid transporters, Excitotoxicity, GLAST, GLT-1, Glutamate, Glutamate transporters",
author = "Edward Pajarillo and Asha Rizor and Jayden Lee and Michael Aschner and Eunsook Lee",
year = "2019",
month = "12",
day = "15",
doi = "10.1016/j.neuropharm.2019.03.002",
language = "English (US)",
volume = "161",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders

T2 - Potential targets for neurotherapeutics

AU - Pajarillo, Edward

AU - Rizor, Asha

AU - Lee, Jayden

AU - Aschner, Michael

AU - Lee, Eunsook

PY - 2019/12/15

Y1 - 2019/12/15

N2 - Glutamate is the primary excitatory neurotransmitter in the central nervous system (CNS) which initiates rapid signal transmission in the synapse before its re-uptake into the surrounding glia, specifically astrocytes. The astrocytic glutamate transporters glutamate-aspartate transporter (GLAST) and glutamate transporter-1 (GLT-1) and their human homologs excitatory amino acid transporter 1 (EAAT1) and 2 (EAAT2), respectively, are the major transporters which take up synaptic glutamate to maintain optimal extracellular glutamic levels, thus preventing accumulation in the synaptic cleft and ensuing excitotoxicity. Growing evidence has shown that excitotoxicity is associated with various neurological disorders, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), manganism, ischemia, schizophrenia, epilepsy, and autism. While the mechanisms of neurological disorders are not well understood, the dysregulation of GLAST/GLT-1 may play a significant role in excitotoxicity and associated neuropathogenesis. The expression and function of GLAST/GLT-1 may be dysregulated at the genetic, epigenetic, transcriptional or translational levels, leading to high levels of extracellular glutamate and excitotoxicity. Consequently, understanding the regulatory mechanisms of GLAST/GLT-1 has been an area of interest in developing therapeutics for the treatment of neurological disorders. Pharmacological agents including β-lactam antibiotics, estrogen/selective estrogen receptor modulators (SERMs), growth factors, histone deacetylase inhibitors (HDACi), and translational activators have shown significant efficacy in enhancing the expression and function of GLAST/GLT-1 and glutamate uptake both in vitro and in vivo. This comprehensive review will discuss the regulatory mechanisms of GLAST/GLT-1, their association with neurological disorders, and the pharmacological agents which mediate their expression and function. This article is part of the issue entitled ‘Special Issue on Neurotransmitter Transporters’.

AB - Glutamate is the primary excitatory neurotransmitter in the central nervous system (CNS) which initiates rapid signal transmission in the synapse before its re-uptake into the surrounding glia, specifically astrocytes. The astrocytic glutamate transporters glutamate-aspartate transporter (GLAST) and glutamate transporter-1 (GLT-1) and their human homologs excitatory amino acid transporter 1 (EAAT1) and 2 (EAAT2), respectively, are the major transporters which take up synaptic glutamate to maintain optimal extracellular glutamic levels, thus preventing accumulation in the synaptic cleft and ensuing excitotoxicity. Growing evidence has shown that excitotoxicity is associated with various neurological disorders, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), manganism, ischemia, schizophrenia, epilepsy, and autism. While the mechanisms of neurological disorders are not well understood, the dysregulation of GLAST/GLT-1 may play a significant role in excitotoxicity and associated neuropathogenesis. The expression and function of GLAST/GLT-1 may be dysregulated at the genetic, epigenetic, transcriptional or translational levels, leading to high levels of extracellular glutamate and excitotoxicity. Consequently, understanding the regulatory mechanisms of GLAST/GLT-1 has been an area of interest in developing therapeutics for the treatment of neurological disorders. Pharmacological agents including β-lactam antibiotics, estrogen/selective estrogen receptor modulators (SERMs), growth factors, histone deacetylase inhibitors (HDACi), and translational activators have shown significant efficacy in enhancing the expression and function of GLAST/GLT-1 and glutamate uptake both in vitro and in vivo. This comprehensive review will discuss the regulatory mechanisms of GLAST/GLT-1, their association with neurological disorders, and the pharmacological agents which mediate their expression and function. This article is part of the issue entitled ‘Special Issue on Neurotransmitter Transporters’.

KW - Astrocytes

KW - EAAT1

KW - EAAT2

KW - Excitatory amino acid transporters

KW - Excitotoxicity

KW - GLAST

KW - GLT-1

KW - Glutamate

KW - Glutamate transporters

UR - http://www.scopus.com/inward/record.url?scp=85066092844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066092844&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2019.03.002

DO - 10.1016/j.neuropharm.2019.03.002

M3 - Review article

C2 - 30851309

AN - SCOPUS:85066092844

VL - 161

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

M1 - 107559

ER -